Skip to content

Moderna MRNA Income Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$2.23B-30.0%$1.94B-39.9%$2.23B-56.1%$3.08B-39.0%$3.18B-38.3%
$1.73B+18.9%$868M-40.7%$1.16B-30.2%$1.46B-56.8%$1.46B-63.5%
$492M-71.4%$1.08B-39.3%$1.08B-68.6%$1.62B-3.2%$1.72B+48.7%
22.1%-32.0pp55.3%+0.6pp48.3%-19.2pp52.5%+19.5pp54.1%+31.7pp
$2.93B-32.5%$3.13B-31.1%$3.48B-27.9%$3.82B-21.3%$4.34B-9.2%
$979M-12.0%$1.02B-13.3%$1.06B-17.9%$1.07B-26.1%$1.11B-26.7%
$5.64B-18.4%$5.02B-30.1%$5.7B-26.7%$6.35B-34.4%$6.91B-32.9%
-$3.41B+8.5%-$3.07B+22.1%-$3.46B-28.3%-$3.27B+29.5%-$3.73B+27.5%
-153.3%-36.0pp-158.1%-36.2pp-155.2%-102pp-106.3%-14.4pp-117.4%-17.5pp
-$22M+69.4%-$8M+90.8%-$25M+74.2%-$37M+72.8%-$72M+24.2%
-$3.14B+7.9%-$2.77B+23.3%-$3.15B-30.1%-$2.95B+33.1%-$3.41B+30.1%
$56M+214%$54M+217%-$37M-$42M-$49M
-$3.19B+4.9%-$2.82B+20.8%-$3.12B-27.7%-$2.9B+52.3%-$3.36B+45.7%
-143.6%-37.9pp-145.2%-35.1pp-139.6%-91.6pp-94.3%+26.2pp-105.7%+14.4pp
-$8.15+6.6%-$7.27+21.7%-$8.07-26.7%-$7.53+52.7%-$8.73+46.2%
-$3.18B+10.2%-$2.86B+23.9%-$3.26B-37.5%-$3.07B+25.5%-$3.54B+22.5%
-142.8%-31.5pp-147.1%-31.0pp-145.8%-99.2pp-99.6%-18.1pp-111.3%-22.7pp
-$3.41B+8.5%-$3.07B+22.1%-$3.46B-28.3%-$3.27B+29.5%-$3.73B+27.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Moderna's revenue?
Moderna (MRNA) generated $2.2B in revenue over the trailing twelve months, down 30.0% year over year.
Is Moderna profitable?
Moderna is not currently profitable: it reported a net loss of $3.2B over the trailing twelve months, a -143.6% net margin.
What are Moderna's profit margins?
Gross margin is 22.1% and operating margin is -153.3%, with a -143.6% net margin.
What is Moderna's earnings per share?
Moderna's diluted EPS over the trailing twelve months is $-8.15.
Where does Moderna's income statement data come from?
Every line is extracted from Moderna's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.